USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
11 Jan 2023 | 03:45 PM GMT

Revenue Generation in Pharma-DTx Partnerships

Anchored by:

Ron Hashomnay
Board Memeber
RXWARE

Participants:

Ron Hashomnay Board MemeberRxWare
Ron Hashomnay
Board MemeberRxWare
Anish Shindore Founder & Managing PartnerGSD Health
Anish Shindore
Founder & Managing PartnerGSD Health
Arshia Gratiot Founder and CEOEupnoos
Arshia Gratiot
Founder and CEOEupnoos
Ashley Pippin DirectorNovartis
Ashley Pippin
DirectorNovartis
Carman Ho Vice PresidentL1 Health
Carman Ho
Vice PresidentL1 Health
Fulvio Michelis Digital Strategy DirectorMerck KGaA
Fulvio Michelis
Digital Strategy DirectorMerck KGaA
Ivan Jurisic Head of ProductPatients Influence
Ivan Jurisic
Head of ProductPatients Influence
Jorge Juan Fernández García Chief Innovation OfficerHospital Clínic Barcelona
Jorge Juan Fernández García
Chief Innovation OfficerHospital Clínic Barcelona
Katie Cannon Director - Strategic PartnershipsAvegen Health
Katie Cannon
Director - Strategic PartnershipsAvegen Health
Mirza Ahmed PartnerBridge-ME
Mirza Ahmed
PartnerBridge-ME
Nita Thingalaya NA Medical Innovation LeadSanofi
Nita Thingalaya
NA Medical Innovation LeadSanofi
Philipp Unruh Digital Product ManagerBayer AG
Philipp Unruh
Digital Product ManagerBayer AG
Ran ken Tor Chief Executive OfficerDermaDetect
Ran ken Tor
Chief Executive OfficerDermaDetect
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Ventsislav Dobrev Global Clinical Lead Digital BiomarkersRoche
Ventsislav Dobrev
Global Clinical Lead Digital BiomarkersRoche

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Many pharma companies have explored partnerships with DTx companies in the last few years, seeking for innovative technologies that add value to their products and services. However, lessons have been learnt and the hype has died down as ROI and outcomes did not meet the initial expectations held by pharma. 

As we enter a new phase where pharma’s approach to DTx has matured and results need to be shown, how can pharma build more effective revenue models when partnering with DTx companies? What is involved in this process? Join this meeting to know more about:

  • Current effective models for revenue generation. What has worked and what hasn't? How have the revenue models evolved over the past few years? 
  • Revenue generation in the short and long term. How can DTx and pharma generate revenue in the short term to show the potential of a longer term partnership? How should the revenue models change over time to support both short and long term goals?
  • Measuring ROI in Pharma-DTx partnerships. How challenging is it to measure the ROI in Pharma-DTx partnerships? What would be an ‘acceptable’ ROI for pharma? And what are the ‘acceptable’ timelines to reach the desired ROI? 
  • Future opportunities for higher revenue in pharma-DTx partnerships. Where in the pharma value chain will we see more opportunities for higher revenue partnerships? What are the technologies and therapeutic areas with more potential for pharma? 
  • Future revenue models. What will revenue generation look like for DTx-Pharma partnerships in a few years time? What is driving this? Will DTx partnerships offer attractive revenue potential to pharma companies?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.